TP53 and cervical cancer: However, miR-22 was found to induce p53 expression and concurrently target SIRT1, CDK6, and Sp1 to activate pRb signaling pathway; thereby hastening senescence, inhibiting cellular growth, invasion, and metastasis in cervical cancer and breast cancer37.